Cargando…

The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput

BACKGROUND: Tracking and understanding artemisinin resistance is key for preventing global setbacks in malaria eradication efforts. The ring-stage survival assay (RSA) is the current gold standard for in vitro artemisinin resistance phenotyping. However, the RSA has several drawbacks: it is relative...

Descripción completa

Detalles Bibliográficos
Autores principales: Davis, Sage Z., Singh, Puspendra P., Vendrely, Katelyn M., Shoue, Douglas A., Checkley, Lisa A., McDew-White, Marina, Button-Simons, Katrina A., Cassady, Zione, Sievert, Mackenzie A. C., Foster, Gabriel J., Nosten, François H., Anderson, Timothy J. C., Ferdig, Michael T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995136/
https://www.ncbi.nlm.nih.gov/pubmed/32005233
http://dx.doi.org/10.1186/s12936-020-3139-6
_version_ 1783493324480446464
author Davis, Sage Z.
Singh, Puspendra P.
Vendrely, Katelyn M.
Shoue, Douglas A.
Checkley, Lisa A.
McDew-White, Marina
Button-Simons, Katrina A.
Cassady, Zione
Sievert, Mackenzie A. C.
Foster, Gabriel J.
Nosten, François H.
Anderson, Timothy J. C.
Ferdig, Michael T.
author_facet Davis, Sage Z.
Singh, Puspendra P.
Vendrely, Katelyn M.
Shoue, Douglas A.
Checkley, Lisa A.
McDew-White, Marina
Button-Simons, Katrina A.
Cassady, Zione
Sievert, Mackenzie A. C.
Foster, Gabriel J.
Nosten, François H.
Anderson, Timothy J. C.
Ferdig, Michael T.
author_sort Davis, Sage Z.
collection PubMed
description BACKGROUND: Tracking and understanding artemisinin resistance is key for preventing global setbacks in malaria eradication efforts. The ring-stage survival assay (RSA) is the current gold standard for in vitro artemisinin resistance phenotyping. However, the RSA has several drawbacks: it is relatively low throughput, has high variance due to microscopy readout, and correlates poorly with the current benchmark for in vivo resistance, patient clearance half-life post-artemisinin treatment. Here a modified RSA is presented, the extended Recovery Ring-stage Survival Assay (eRRSA), using 15 cloned patient isolates from Southeast Asia with a range of patient clearance half-lives, including parasite isolates with and without kelch13 mutations. METHODS: Plasmodium falciparum cultures were synchronized with single layer Percoll during the schizont stage of the intraerythrocytic development cycle. Cultures were left to reinvade to early ring-stage and parasitaemia was quantified using flow cytometry. Cultures were diluted to 2% haematocrit and 0.5% parasitaemia in a 96-well plate to start the assay, allowing for increased throughput and decreased variability between biological replicates. Parasites were treated with 700 nM of dihydroartemisinin or 0.02% dimethyl sulfoxide (DMSO) for 6 h, washed three times in drug-free media, and incubated for 66 or 114 h, when samples were collected and frozen for PCR amplification. A SYBR Green-based quantitative PCR method was used to quantify the fold-change between treated and untreated samples. RESULTS: 15 cloned patient isolates from Southeast Asia with a range of patient clearance half-lives were assayed using the eRRSA. Due to the large number of pyknotic and dying parasites at 66 h post-exposure (72 h sample), parasites were grown for an additional cell cycle (114 h post-exposure, 120 h sample), which drastically improved correlation with patient clearance half-life compared to the 66 h post-exposure sample. A Spearman correlation of − 0.8393 between fold change and patient clearance half-life was identified in these 15 isolates from Southeast Asia, which is the strongest correlation reported to date. CONCLUSIONS: eRRSA drastically increases the efficiency and accuracy of in vitro artemisinin resistance phenotyping compared to the traditional RSA, which paves the way for extensive in vitro phenotyping of hundreds of artemisinin resistant parasites.
format Online
Article
Text
id pubmed-6995136
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69951362020-02-04 The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput Davis, Sage Z. Singh, Puspendra P. Vendrely, Katelyn M. Shoue, Douglas A. Checkley, Lisa A. McDew-White, Marina Button-Simons, Katrina A. Cassady, Zione Sievert, Mackenzie A. C. Foster, Gabriel J. Nosten, François H. Anderson, Timothy J. C. Ferdig, Michael T. Malar J Methodology BACKGROUND: Tracking and understanding artemisinin resistance is key for preventing global setbacks in malaria eradication efforts. The ring-stage survival assay (RSA) is the current gold standard for in vitro artemisinin resistance phenotyping. However, the RSA has several drawbacks: it is relatively low throughput, has high variance due to microscopy readout, and correlates poorly with the current benchmark for in vivo resistance, patient clearance half-life post-artemisinin treatment. Here a modified RSA is presented, the extended Recovery Ring-stage Survival Assay (eRRSA), using 15 cloned patient isolates from Southeast Asia with a range of patient clearance half-lives, including parasite isolates with and without kelch13 mutations. METHODS: Plasmodium falciparum cultures were synchronized with single layer Percoll during the schizont stage of the intraerythrocytic development cycle. Cultures were left to reinvade to early ring-stage and parasitaemia was quantified using flow cytometry. Cultures were diluted to 2% haematocrit and 0.5% parasitaemia in a 96-well plate to start the assay, allowing for increased throughput and decreased variability between biological replicates. Parasites were treated with 700 nM of dihydroartemisinin or 0.02% dimethyl sulfoxide (DMSO) for 6 h, washed three times in drug-free media, and incubated for 66 or 114 h, when samples were collected and frozen for PCR amplification. A SYBR Green-based quantitative PCR method was used to quantify the fold-change between treated and untreated samples. RESULTS: 15 cloned patient isolates from Southeast Asia with a range of patient clearance half-lives were assayed using the eRRSA. Due to the large number of pyknotic and dying parasites at 66 h post-exposure (72 h sample), parasites were grown for an additional cell cycle (114 h post-exposure, 120 h sample), which drastically improved correlation with patient clearance half-life compared to the 66 h post-exposure sample. A Spearman correlation of − 0.8393 between fold change and patient clearance half-life was identified in these 15 isolates from Southeast Asia, which is the strongest correlation reported to date. CONCLUSIONS: eRRSA drastically increases the efficiency and accuracy of in vitro artemisinin resistance phenotyping compared to the traditional RSA, which paves the way for extensive in vitro phenotyping of hundreds of artemisinin resistant parasites. BioMed Central 2020-01-31 /pmc/articles/PMC6995136/ /pubmed/32005233 http://dx.doi.org/10.1186/s12936-020-3139-6 Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Methodology
Davis, Sage Z.
Singh, Puspendra P.
Vendrely, Katelyn M.
Shoue, Douglas A.
Checkley, Lisa A.
McDew-White, Marina
Button-Simons, Katrina A.
Cassady, Zione
Sievert, Mackenzie A. C.
Foster, Gabriel J.
Nosten, François H.
Anderson, Timothy J. C.
Ferdig, Michael T.
The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput
title The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput
title_full The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput
title_fullStr The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput
title_full_unstemmed The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput
title_short The extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput
title_sort extended recovery ring-stage survival assay provides a superior association with patient clearance half-life and increases throughput
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6995136/
https://www.ncbi.nlm.nih.gov/pubmed/32005233
http://dx.doi.org/10.1186/s12936-020-3139-6
work_keys_str_mv AT davissagez theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT singhpuspendrap theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT vendrelykatelynm theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT shouedouglasa theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT checkleylisaa theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT mcdewwhitemarina theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT buttonsimonskatrinaa theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT cassadyzione theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT sievertmackenzieac theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT fostergabrielj theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT nostenfrancoish theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT andersontimothyjc theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT ferdigmichaelt theextendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT davissagez extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT singhpuspendrap extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT vendrelykatelynm extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT shouedouglasa extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT checkleylisaa extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT mcdewwhitemarina extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT buttonsimonskatrinaa extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT cassadyzione extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT sievertmackenzieac extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT fostergabrielj extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT nostenfrancoish extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT andersontimothyjc extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput
AT ferdigmichaelt extendedrecoveryringstagesurvivalassayprovidesasuperiorassociationwithpatientclearancehalflifeandincreasesthroughput